Lee D, Cho M, Kim E, Seo Y, Cha JH. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32:4235–55.
Google Scholar
Mandal K, Barik GK, Santra MK. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Mol Cancer. 2025;24:246.
Google Scholar
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345–62.
Google Scholar
Davick JJ, Frierson HF, Smolkin M, Gru AA. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. Hum Pathol. 2018;81:184–91.
Google Scholar
Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy. Mol Cancer. 2024;23:183.
Google Scholar
Wang Y, He M, Li J, Li L. Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review. Front Immunol. 2025;16:1591379.
Google Scholar
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024;23:108.
Google Scholar
Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287–305.
Google Scholar
Ding P, Ma Z, Fan Y, Feng Y, Shao C, Pan M, et al. Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy. Genes Dis. 2023;10:848–63.
Google Scholar
Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X. Emerging role of ubiquitination in the regulation of PD-1/PD-L1 in cancer immunotherapy. Mol Ther. 2021;29:908–19.
Google Scholar
Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–5.
Google Scholar
Wei M, Mo Y, Liu J, Zhai J, Li H, Xu Y, et al. Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation. Front Oncol. 2022;12:835603.
Google Scholar
Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell–mediated bladder cancer immune surveillance. Cancer Res. 2022;82:114–29.
Google Scholar
Zhang YJ, Xiong SP, Yang YZ, Fu S, Wang TM, Suster DI, et al. Clinicopathologic features, tumor immune microenvironment and genomic landscape of EBV-related and EBV-unrelated poorly differentiated nonkeratinizing squamous cell carcinoma of the thymus. Lung Cancer. 2023;179:107178.
Google Scholar
Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020;52:177–86.
Google Scholar
Cheng Y, Sun Q, Chen Y, Wang J, Chen Y, Yang Y, et al. DTX3 suppresses bladder cancer cell invasion and metastasis by inhibiting the Notch signaling pathway. Int Immunopharmacol. 2025;153:114529.
Google Scholar
Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S, et al. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK-positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology. 2016;5:e1094598.
Google Scholar
Cheng Y, Hu Y, Wang H, Zhao Z, Jiang X, Zhang Y, et al. Ring finger protein 19A is overexpressed in non-small cell lung cancer and mediates p53 ubiquitin-degradation to promote cancer growth. J Cell Mol Med. 2021;25:7796–808.
Google Scholar
Cheng Y, Li S, Li X, Xue J, Hao M, Zhou L, et al. RNF19A facilitates gastric cancer progression by regulating the Hippo/YAP axis. Int Immunopharmacol. 2026;171:116169.
Google Scholar
Galardi S, Mercatelli N, Farace MG, Ciafre SA. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 2011;39:3892–902.
Google Scholar
Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, Pavlopoulos P, et al. Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Arch. 2008;452:295–304.
Google Scholar
Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F. Regulation of PD-L1 expression by NF-κB in cancer. Front Immunol. 2020;11:584626.
Google Scholar
Scalia P, Williams SJ, Suma A, Carnevale V. The DTX protein family: an emerging set of E3 ubiquitin ligases in cancer. Cells. 2023;12:1680.
Google Scholar
Busseau I, Diederich RJ, Xu T, Artavanis-Tsakonas S. A member of the Notch group of interacting loci, deltex encodes a cytoplasmic basic protein. Genetics. 1994;136:585–96.
Google Scholar
Chatrin C, Gabrielsen M, Buetow L, Nakasone MA, Ahmed SF, Sumpton D, et al. Structural insights into ADP-ribosylation of ubiquitin by Deltex family E3 ubiquitin ligases. Sci Adv. 2020;6:eabc0418.
Google Scholar
Xu H, Liang S, Hu J, Liu W, Dong Z, Wei S. Deltex E3 ubiquitin ligase 3 inhibits colorectal cancer cell growth and regulates cell cycle progression via upregulating E2F transcription factor 1. Mol Biol Rep. 2022;49:1661–68.
Google Scholar
Wang L, Huang Y, Liu C, Guo M, Ma Z, He J, et al. Deltex3 inhibits epithelial- mesenchymal transition in papillary thyroid carcinoma via promoting ubiquitination of XRCC5 to regulate the AKT signal pathway. J Cancer. 2021;12:860–73.
Google Scholar
Ding XY, Hu HY, Huang KN, Wei RQ, Min J, Qi C, et al. Ubiquitination of NOTCH2 by DTX3 suppresses the proliferation and migration of human esophageal carcinoma. Cancer Sci. 2020;111:489–501.
Google Scholar
Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF. Intratumoral CD8+ T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity. Cancer Immunol Res. 2018;6:14–24.
Google Scholar
Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, et al. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transpl. 2007;7:2683–92.
Google Scholar
Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 2022;185:4049–66.e25.
Google Scholar
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.
Google Scholar
Jin M, Fang J, Peng J, Wang X, Xing P, Jia K, et al. PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23:266.
Google Scholar
Lee TA, Tsai EY, Liu SH, Chou WC, Hsu Hung SD, Chang CY, et al. Regulation of PD-L1 glycosylation and advances in cancer immunotherapy. Cancer Lett. 2025;612:217498.
Google Scholar
Zhang Y, Zeng L, Wang M, Yang Z, Zhang H, Gao L, et al. RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination. J Immunother Cancer. 2023;11:e007313.
Google Scholar
Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z, et al. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nat Commun. 2022;13:6951.
Google Scholar
Sun Z, Mai H, Xue C, Fan Z, Li J, Chen H, et al. Hsa-LINC02418/mmu-4930573I07Rik, regulated by METTL3, dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination. J Immunother Cancer. 2023;11:e007415.
Google Scholar
Ho S-R, Lee Y-C, Ittmann MM, Lin F-T, Chan KS, Lin W-C. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Lett. 2021;520:344–60.
Google Scholar
Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, et al. Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma. Cancer Res. 2015;75:4384–97.
Google Scholar
Wang D, Sang Y, Sun T, Kong P, Zhang L, Dai Y, et al. Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review). Int J Oncol. 2021;58:20.
Google Scholar
Zeng LP, Hu ZM, Li K, Xia K. miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells. J Cell Mol Med. 2016;20:559–67.
Google Scholar
Zhang DQ, Zhou CK, Jiang XW, Chen J, Shi BK. Increased expression of miR-222 is associated with poor prognosis in bladder cancer. World J Surg Oncol. 2014;12:241.
Google Scholar
Cui X, Shen D, Kong C, Zhang Z, Zeng Y, Lin X, et al. NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo. Sci Rep. 2017;7:40723.
Google Scholar
Aggarwal BB, Sung B. NF-κB in cancer: a matter of life and death. Cancer Discov. 2011;1:469–71.
Google Scholar
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.
Google Scholar
Zhou Y, Jin X, Yu H, Qin G, Pan P, Zhao J, et al. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Theranostics. 2022;12:2080–94.
Google Scholar
Zeng X, Tang X, Chen X, Wen H. RNF182 induces p65 ubiquitination to affect PDL1 transcription and suppress immune evasion in lung adenocarcinoma. Immun Inflamm Dis. 2023;11:e864.
Google Scholar
Wu W, Chen L, Jia G, Tang Q, Han B, Xia S, et al. Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer. Cancer Med. 2023;12:15676–90.
Google Scholar
